生物制药公司89Bio, Inc.（ETNB）今日盘中大跌5.65%，投资者对公司最新公布的季度业绩表示失望。
根据公司公告，89Bio截至6月30日的季度调整后每股亏损为0.71美元，大幅超过分析师平均预期的0.49美元亏损。这已经是公司连续第四个季度未能达到盈利预期。当季公司总亏损达1.115亿美元，而收入则为零。这一疲软的业绩表现引发了投资者的担忧，导致股价下跌。
尽管89Bio的股价今日遭遇重挫，但值得注意的是，该公司股票今年以来仍上涨了21.2%。此外，分析师对公司前景仍保持乐观态度，目前对该股的平均评级为"买入"。华尔街分析师给出的12个月目标价中位数为28.00美元，较当前股价有显著上涨空间。这表明尽管短期内公司面临挑战，但长期发展潜力仍被看好。投资者将密切关注89Bio未来的业绩表现，以评估公司能否扭转局面，实现盈利预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.